William P. Sheridan
2020
In 2020, William P. Sheridan earned a total compensation of $2.7M as Chief Medical Officer at BioCryst Pharmaceuticals, a 151% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $257,573 |
|---|---|
| Option Awards | $1,892,951 |
| Salary | $515,146 |
| Other | $14,250 |
| Total | $2,679,920 |
Sheridan received $1.9M in option awards, accounting for 71% of the total pay in 2020.
Sheridan also received $257.6K in non-equity incentive plan, $515.1K in salary and $14.3K in other compensation.
Rankings
In 2020, William P. Sheridan's compensation ranked 4,282nd out of 13,090 executives tracked by ExecPay. In other words, Sheridan earned more than 67.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,282 out of 13,090 | 67th |
Division Manufacturing | 1,734 out of 5,624 | 69th |
Major group Chemicals And Allied Products | 676 out of 2,257 | 70th |
Industry group Drugs | 577 out of 1,957 | 71st |
Industry Biological Products, Except Diagnostic Substances | 133 out of 411 | 68th |
Source: SEC filing on April 25, 2022.
Sheridan's colleagues
We found four more compensation records of executives who worked with William P. Sheridan at BioCryst Pharmaceuticals in 2020.